- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01365221
The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel (SWITCH 600/60)
SWITCH 600/60: The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, open-label, non-randomized trial of approximately 260 patients with Acute Coronary Syndrome (ACS) undergoing percutaneous coronary intervention (PCI). In order to compare platelet reactivity, as assessed by the VerifyNow P2Y12 assay, we plan to recruit two study groups of interest:
- Patients who have already received a 600 mg loading dose (LD) of clopidogrel in preparation for PCI will receive a loading dose of 60 mg of prasugrel.
- Patients who have not received a LD of clopidogrel will receive a 60 mg LD of prasugrel prior to PCI.
A subset of 40 patients from each study group (80 patients total) will undergo additional platelet reactivity testing with the vasodilator stimulated phosphoprotein (VASP) assay.All patients will be followed throughout the duration of the hospital stay.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alabama
-
Huntsville, Alabama, United States, 35801
- The Heart Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washington Hospital Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21215
- Sinai Center for Thrombosis Research
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Saint Luke's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients age 18 or older, of both genders
Presenting with an ACS, defined as at least two of the following:
Symptoms consistent with myocardial ischemia; ST segment elevation or depression of at least 1 mm in 2 or more contiguous leads on EKG; Cardiac troponin I level above the upper limit of normal.
- An initial invasive strategy (e.g. early angiography) is planned.
- No contraindications to prasugrel therapy.
Exclusion Criteria:
- Known allergies to aspirin, clopidogrel, or prasugrel.
- Patient known to be pregnant or lactating.
- Patient with known history of bleeding diathesis, or currently active bleeding.
- Platelet count <100,000/mm3 at the time of enrollment.
- Hematocrit <25% at the time of enrollment.
- On warfarin therapy at the time of PCI, or patient likely to require warfarin therapy post-PCI.
- Received fibrinolytics within the past 48 hours.
- Received a glycoprotein IIb/IIIa inhibitor within the past 48 hours, or if a strategy for PCI involving a glycoprotein IIb/IIIa inhibitor is planned.
- Taking maintenance thienopyridine therapy in the previous 7 days.
- Known blood transfusion within the preceding 10 days.
- Patients treated with non-steroidal anti-inflammatory drugs (NSAIDS) within the previous 5 days.
- Patients with known chronic liver disease.
- Age greater than 75 years.
- Body weight less than 60 kg.
- History of stroke or transient ischemic attack.
- Surgery planned within 1 month.
- Patient likely to require coronary artery bypass grafting.
- Any significant medical condition that, in the investigator's opinion, may interfere with the patient's optimal participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients who have received loading dose of clopidogrel
|
Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
|
Active Comparator: Patients who have not received loading dose of clopidogrel
|
Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary objective is to compare platelet reactivity, as assessed by the VerifyNow P2Y12 assay, between patients receiving a loading dose of clopidogrel and a reloading dose of prasugrel to patients receiving only a loading dose of prasugrel.
Time Frame: Average hospital stay is 24-48 hours.
|
Average hospital stay is 24-48 hours.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The secondary objective of this study is to describe rates of bleeding events associated with a loading dose of prasugrel in patients who have already received a loading dose of clopidogrel.
Time Frame: Average hospital stay is 24-48 hours.
|
Average hospital stay is 24-48 hours.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ron Waksman, MD, MedStar Washington Hospital Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SWITCH 600/60
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
Deutsches Herzzentrum MuenchenDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)CompletedAcute Coronary Syndrome (ACS)Germany, Italy
-
Northwestern UniversityTerminatedACS - Acute Coronary SyndromeUnited States
Clinical Trials on Prasugrel
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.Completed
-
Maasstad HospitalDaiichi Sankyo, Inc.; MicroPort Orthopedics Inc.; Research Maatschap Cardiologen...CompletedCardiovascular DiseasesNetherlands
-
University of PatrasCompleted
-
Gyeongsang National University HospitalCompletedBleeding | Acute Coronary Syndrome | Platelet ThrombusKorea, Republic of
-
University of MilanCompleted
-
University of FloridaCompletedCoronary Artery DiseaseUnited States
-
VA Office of Research and DevelopmentCompletedCoronary Artery BypassUnited States
-
Research Maatschap Cardiologen Rotterdam ZuidAbbott Medical DevicesRecruitingST Elevated Myocardial Infarction | Dual Antiplatelet TherapyNetherlands, Germany, Italy
-
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo CompanyCompletedAcute Coronary Syndrome (ACS)Taiwan